版本:
中国

BRIEF-Abbvie says investigational IL-23 inhibitor Risankizumab receives Orphan Drug Designation from U.S. FDA

Nov 30 Abbvie Inc :

* Abbvie receives Orphan Drug Designation for investigational IL-23 inhibitor Risankizumab from the U.S. Food and Drug Administration for the treatment of pediatric patients with Crohn's Disease Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐